caa a22 4500 475824539 CHVBK 20180406123827.0 cr unu---uuuuu 170329e20001201xx s 000 0 eng 10.1023/A:1026591023462 doi (NATIONALLICENCE)springer-10.1023/A:1026591023462 Argatroban and Alteplase in Patients with Acute Myocardial Infarction: The ARGAMI Study [Elektronische Daten] [Frank Vermeer, Alec Vahanian, Phonse Fels, Pierre Besse, Evert Müller, Frans Van de Werf, Detmond Fitzgerald, Harald Darius, Jean Puel, Desirée Garrigou, Maarten Simoons] ARGAMI was designed to assess safety and efficacy of argatroban compared with heparin as adjunctive treatment to alteplase in the treatment of patients with acute myocardial infarction. ARGAMI consisted of an open-dose finding study (35 patients) followed by a placebo-controlled study with double dummy technique and 2:1 (argatroban:heparin) randomization. An argatroban dosage of 100 μg/kg bolus plus 3 μg/kg/min infusion for 72 hours was selected for the randomized study in which 82 patients were allocated to argatroban and 45 to heparin (5000 U intravenous bolus, 1000 U/h infusion). Patency of the infarct-related artery (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3 flow) after 90 minutes was obtained in 62 patients (76%) allocated to argatroban versus 37 patients (82%) allocated to heparin (p=ns). Angiograms after 24 hours and 5 to 10 days showed low reocclusion rates in both groups. Bleeding complications were observed in 16 patients allocated to argatroban (19.5%) and in 9 patients allocated to heparin (20.0%). One patient allocated to heparin suffered from hemorrhage stroke. Argatroban, given as adjunctive treatment to alteplase, is tolerated well in patients with acute myocardial infarction. Safety and efficacy of the combination alteplase and argatroban (with this dose regimen) are similar to those of alteplase and heparin. Kluwer Academic Publishers, 2000 argatroban nationallicence thrombin inhibitor nationallicence alteplase nationallicence angiography nationallicence reocclusion nationallicence Vermeer Frank University Hospital, Maastricht, The Netherlands aut Vahanian Alec Hôpital Tenon, Paris, France aut Fels Phonse Drechtsteden Ziekenhuis, Dordrecht, The Netherlands aut Besse Pierre Groupe Hospitalier Xavier-Arnozan, Pessac, France aut Müller Evert Spaarne Ziekenhuis, Heemstede, The Netherlands aut Van de Werf Frans University Hospital, Leuven, Belgium aut Fitzgerald Detmond Royal College of Surgeons in Ireland, Dublin, Ireland aut Darius Harald University Hospital, Mainz, Germany aut Puel Jean Hôpital Purpan, Toulouse, France aut Garrigou Desirée Synthelabo Recherche, Paris, France aut Simoons Maarten University Hospital Rotterdam, The Netherlands aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/3(2000-12-01), 233-240 0929-5305 10:3<233 2000 10 11239 https://doi.org/10.1023/A:1026591023462 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1026591023462 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vermeer Frank University Hospital, Maastricht, The Netherlands aut NATIONALLICENCE 700 1- Vahanian Alec Hôpital Tenon, Paris, France aut NATIONALLICENCE 700 1- Fels Phonse Drechtsteden Ziekenhuis, Dordrecht, The Netherlands aut NATIONALLICENCE 700 1- Besse Pierre Groupe Hospitalier Xavier-Arnozan, Pessac, France aut NATIONALLICENCE 700 1- Müller Evert Spaarne Ziekenhuis, Heemstede, The Netherlands aut NATIONALLICENCE 700 1- Van de Werf Frans University Hospital, Leuven, Belgium aut NATIONALLICENCE 700 1- Fitzgerald Detmond Royal College of Surgeons in Ireland, Dublin, Ireland aut NATIONALLICENCE 700 1- Darius Harald University Hospital, Mainz, Germany aut NATIONALLICENCE 700 1- Puel Jean Hôpital Purpan, Toulouse, France aut NATIONALLICENCE 700 1- Garrigou Desirée Synthelabo Recherche, Paris, France aut NATIONALLICENCE 700 1- Simoons Maarten University Hospital Rotterdam, The Netherlands aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/3(2000-12-01), 233-240 0929-5305 10:3<233 2000 10 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer